Article thumbnail

Prognostic Impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

By Sean M. Post, Vinod Pant, Hussein Abbas and Alfonso Quintás-Cardama


A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date

Topics: Reviews
Publisher: Impact Journals LLC
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A Mouse Model for the Human MDM2SNP309 Polymorphism.
  2. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
  3. (2004). Acute lymphoblastic leukemia.
  4. (1992). Amplification of a gene encoding a 173 Oncotarget 2010; 1: 168-174 p53-associated protein in human sarcomas.
  5. (2008). Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
  6. (2005). Chronic lymphocytic leukemia.
  7. (2008). Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood
  8. (2005). Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell
  9. (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
  10. (2010). Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One
  11. (1998). Functional and physical interactions between the estrogen receptor Sp1 and nuclear aryl hydrocarbon receptor complexes. Nucl. Acids Res.
  12. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia.
  13. (2007). High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol
  14. (2002). Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
  15. (2007). Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309. Haematologica
  16. (2007). interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res
  17. (2008). interact to alter therapy-related acute myeloid leukemia susceptibility. Blood
  18. (2009). Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res
  19. (2003). mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol
  20. (2010). MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer
  21. (2005). MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia
  22. (2006). MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res
  23. (2008). MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients.
  24. (2008). MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
  25. (2010). MDM2 SNP309 promoter polymorphism, an independent prognostic factor in Chronic Lymphocytic Leukemia. Eur J Haematol
  26. (2003). MDM2, an introduction. Mol Cancer Res
  27. (2010). microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood
  28. (2008). not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.
  29. (2005). p53 mutation heterogeneity in cancer.
  30. (2007). p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet
  31. (2009). Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res
  32. SNP309 as predictor for sensitivity of CLL 174 Oncotarget 2010; 1: 168-174 cells to the MDM2 inhibitor nutlin-3a. Blood 2008; 112: 2168; author reply 2169.
  33. SNP309 associates with accelerated pancreatic adenocarcinoma formation. Pancreas
  34. (2000). Surfing the p53 network. Nature
  35. (2008). The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica
  36. (1985). The origin of B-chronic lymphocytic leukaemia (B-CLL) and its relationship to hairy cell leukaemia (HCL). Adv Exp Med Biol
  37. (2009). TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet